News

EU Approval – Misoprostol Tablet for Induction of Labour

AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care

Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment

AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care

Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment

Lunatus and AFYX Therapeutics A/S Announce Distribution and Sales Collaboration

EU Approval – Misoprostol Tablet for Induction of Labour

AFYX Therapeutics Receives EU Approval for Its Low-Dose Oral Misoprostol Tablet for Induction of Labour in 20 European Countries and Northern Ireland. Hørsholm, Denmark – 4 May 2026 AFYX Therapeutics A/S (“AFYX”), a Danish specialty pharmaceutical company focused on...

AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care

PRESS RELEASE AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care for distribution in South Africa and Sub-Saharan Africa. Copenhagen, Denmark – January 22, 2026. AFYX Therapeutics has entered a strategic distribution partnership with...

Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment

PRESS RELEASE Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025 FOR IMMEDIATE RELEASE - Date: May 5th, 2025 Clinical Study Demonstrates Improved Locoregional Control with Nimorazole in...